XML 46 R34.htm IDEA: XBRL DOCUMENT v3.20.2
Related Party Transactions (Narrative) (Details)
3 Months Ended
Aug. 03, 2020
May 18, 2020
USD ($)
Dec. 30, 2019
USD ($)
Dec. 27, 2019
USD ($)
director
day
shares
Jun. 04, 2019
USD ($)
$ / shares
shares
Jun. 30, 2020
USD ($)
shares
Jun. 30, 2019
USD ($)
Aug. 05, 2020
USD ($)
Related Party Transaction [Line Items]                
Proceeds from related party debt financing           $ 80,000,000 $ 0  
Interest expense (related party)           $ 2,184,000 0  
Sumitomo Dainippon Pharma Co., Ltd. | Majority Shareholder                
Related Party Transaction [Line Items]                
Number of shares owned (in shares) | shares       45,008,604   48,641,181    
Ownership percentage       50.20%   54.00%    
Ownership threshold for appointment of directors       50.00%        
Number of independing directors required for audit commitee | director       3        
Ownership threshold for voting rights       60.00%        
Ownership threshold for right of ownership percentage maintenance       50.00%        
Sumitomo Dainippon Pharma Co., Ltd. | Majority Shareholder | Sumitovant Consulting Agreement                
Related Party Transaction [Line Items]                
Termination notice period   15 days            
Maximum fees   $ 120,000            
Expenses incurred under agreements           $ 114,000    
Roivant Sciences, Ltd. | Majority Shareholder | Service Agreement                
Related Party Transaction [Line Items]                
Expenses incurred under agreements             200,000  
Roivant Sciences, Ltd. | Majority Shareholder | Share-based Compensation, Expense Allocated to Company                
Related Party Transaction [Line Items]                
Expenses incurred under agreements           0 100,000  
Public Offering                
Related Party Transaction [Line Items]                
Number of shares issued (in shares) | shares         17,424,243      
Price of shares (in USD per share) | $ / shares         $ 8.25      
Net proceeds from sale of shares         $ 134,500,000      
Public Offering | Roivant Sciences, Ltd. | Majority Shareholder                
Related Party Transaction [Line Items]                
Number of shares issued (in shares) | shares         2,424,242      
Price of shares (in USD per share) | $ / shares         $ 8.25      
Net proceeds from sale of shares         $ 20,000,000.0      
Term Loan | Letter Agreement with Sumitomo Dainippon Pharma, Co., Ltd. | Sumitomo Dainippon Pharma Co., Ltd. | Majority Shareholder                
Related Party Transaction [Line Items]                
Maximum borrowing commitment       $ 400,000,000.0        
Proceeds from related party debt financing     $ 113,700,000          
Facility term       5 years        
Notice period for prepayment | day       10        
Default interest rate       5.00%        
Repayment period upon change in control       30 days        
Outstanding balance           193,700,000    
Available borrowing capacity           206,300,000    
Interest expense (related party)           $ 2,200,000 $ 0  
Term Loan | New Letter Agreement with Sumitomo Dainippon Pharma, Co., Ltd. | Sumitomo Dainippon Pharma Co., Ltd. | Majority Shareholder | Subsequent Event                
Related Party Transaction [Line Items]                
Maximum borrowing commitment               $ 200,000,000.0
Facility term 5 years              
LIBOR | Term Loan | Letter Agreement with Sumitomo Dainippon Pharma, Co., Ltd. | Sumitomo Dainippon Pharma Co., Ltd. | Majority Shareholder                
Related Party Transaction [Line Items]                
Variable interest rate       3.00%